Program Planning and Evaluation

青年协进会的内部和外部咨询小组在规划和评估方面提供了宝贵的指导 自上一次NCI CCSG审查以来，特别是最近三年， 自从任命新主任以来。将内科肿瘤置于 YCC需要仔细的战略规划，以招募和整合大量新的临床骨干， investigators.整个咨询小组为新的基础研究空间的设计做出了巨大贡献， 以及毗邻的新临床设施，包括一座耗资4.6亿美元的14层楼高的临床癌症中心大楼。的 外部科学咨询委员会（ESAB）和多层内部咨询小组在以下方面发挥了重要作用： 研究计划沿着主题进行重组。在临床上的实质性改善 试验基础设施，以支持不断扩大的制药商发起的临床试验工作，需要仔细 规划和评价。司长修改和改进了决策网络， 咨询小组。高级领导小组由主任、副主任和4名 协理主任，每周开会评价各项举措的进展情况。执行委员会每月举行会议 考虑和评估所有重要举措的进展情况，包括机构和研究计划 领导者，加上。一个新的科学指导委员会，由基础教育司副司长担任主席， 科学，监督资源分配给研究计划，包括8个指定的目标 卓越研究领域。一个新的临床研究指导委员会，由助理 临床科学总监，为临床翻译项目设定优先顺序。伊萨一直在 随着几位经验丰富的癌症中心主任的加入而扩大，现在包括12名成员， 在基础科学、转化科学和人口科学方面具有互补的专业知识。这个外部咨询小组 在青年团体所有关键活动的规划和评估中发挥了不可或缺的作用。一个委员会，由 副主任，协调30多个新颖的试点项目的年度选择， 非CCSG来源，由个别研究计划负责人推荐后。这些协调一致的 顾问团队提供重要的建议和指导，确保青年协调委员会能够最有效地制定 优先事项和追求有助于塑造癌症预防，诊断和治疗领域的目标。

The YCC internal and external advisory groups have provided invaluable guidance in planning and evaluation of all of the major initiatives since the last NCI CCSG review, particularly during the most recent three years since the appointment of the new Director. Placement of Medical Oncology under the operational control of the YCC required careful strategic planning for the recruitment and integration of a large new cadre of clinical investigators. The entire set of advisory groups contributed heavily to the design of new basic research space, as well as adjacent new clinical facilities, including a $460 million, 14-story Clinical Cancer Center Tower. The External Scientific Advisory Board (ESAB) and multiple layers of internal advisory groups were instrumental in the reorganization of the Research Programs along thematic lines. Substantial improvements in the clinical trials infrastructure, to support the expanding investigator-initiated clinical trials efforts, required careful planning and evaluation. The Director has modified and improved the network of decision-making and advisory groups. The Senior Leadership Team (SLT) composed of the Director, Deputy Director, and the 4 Associate Directors, meets weekly to evaluate progress in initiatives. The Executive Committee meets monthly to consider and evaluate progress of all important initiatives and includes institutional and Research Program Leaders, plus the SLT. A new Scientific Steering Committee, chaired by the Associate Director of Basic Science, oversees the allocation of resources to research initiatives, including the 8 designated Targeted Areas of Research Excellence. A new Clinical Research Steering Committee, chaired by the Associate Director of Clinical Science, sets priorities for the clinical translational programs. The ESAB has been expanded with the addition of several experienced Cancer Center Directors and now includes 12 members, with complementary expertise in basic, translational, and population sciences. This external advisory group has played an integral role in planning and evaluation of all pivotal YCG activities. A committee, chaired by the Deputy Director, coordinates the annual selection of more than 30 novel Pilot Projects, supported from three non-CCSG sources, after recommendation by individual Research Program Leaders. These coordinated teams of advisors provide critical advice and guidance, ensuring that the YCC can most effectively set priorities and pursue objectives that help shape the fields of cancer prevention, diagnosis, and treatment.